AbbVie Inc. $ABBV Shares Sold by Willis Johnson & Associates Inc.

Willis Johnson & Associates Inc. decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 43.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 1,844 shares of the company’s stock after selling 1,413 shares during the quarter. Willis Johnson & Associates Inc.’s holdings in AbbVie were worth $342,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ABBV. FF Advisors LLC boosted its stake in shares of AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock valued at $286,000 after buying an additional 53 shares during the last quarter. Landaas & Co. WI ADV increased its stake in shares of AbbVie by 1.1% in the second quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock worth $920,000 after buying an additional 53 shares during the last quarter. Bernardo Wealth Planning LLC raised its holdings in AbbVie by 2.9% in the second quarter. Bernardo Wealth Planning LLC now owns 1,909 shares of the company’s stock valued at $354,000 after acquiring an additional 53 shares in the last quarter. LifeSteps Financial Inc. boosted its stake in AbbVie by 0.7% during the 2nd quarter. LifeSteps Financial Inc. now owns 7,358 shares of the company’s stock valued at $1,366,000 after acquiring an additional 54 shares during the last quarter. Finally, Silicon Valley Capital Partners grew its holdings in AbbVie by 10.8% during the 1st quarter. Silicon Valley Capital Partners now owns 573 shares of the company’s stock worth $118,000 after acquiring an additional 56 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV opened at $226.72 on Monday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a market cap of $400.69 billion, a price-to-earnings ratio of 107.96, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The firm has a fifty day moving average of $227.71 and a 200-day moving average of $207.01.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter last year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s dividend payout ratio is currently 524.24%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Bank of America upped their price objective on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Citigroup reduced their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. UBS Group upped their price target on AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Finally, Raymond James Financial set a $256.00 price objective on AbbVie in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $241.85.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.